CSPC Pharmaceutical Group’s Stock Price Drops to 5.74 HKD, Down by 1.71%

CSPC Pharmaceutical Group (1093)

5.74 HKD -0.10 (-1.71%) Volume: 153.58M

CSPC Pharmaceutical Group’s stock price is currently valued at 5.74 HKD, experiencing a slight dip of -1.71% this trading session, with a considerable trading volume of 153.58M. Despite the recent drop, the company showcases a robust yearly performance with a +20.08% change YTD, underlining its steady growth in the pharmaceutical industry.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group‘s stock price is expected to see movement as CLSA has raised its target price to HK$13.80. This comes after a series of positive events leading up to this decision, including strong financial performance, successful product launches, and promising developments in the pharmaceutical industry. Investors are closely watching the company as it continues to demonstrate growth potential and solidify its position in the market.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With a high score in Dividend and Momentum, the company is deemed to be performing well in terms of profitability and market performance. Additionally, CSPC Pharmaceutical Group scores well in Value and Resilience, indicating strong financials and stability. However, the Growth score is slightly lower, suggesting potential room for improvement in expanding its business and product offerings.

CSPC Pharmaceutical Group Limited, a company known for manufacturing and selling pharmaceutical products such as vitamin C, antibiotics, and generic drugs, is also involved in the development of innovative drugs and antibiotics. With its impressive Smartkarma Smart Scores across various factors, CSPC Pharmaceutical Group appears to be on a solid path for future growth and success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma